Immupharma Share Discussion Threads

[cammy5] 06/4/2018 23:45

I retirement , what you trying to say

[l0ngterm] 06/4/2018 23:16

You bore me

[1retirement] 06/4/2018 23:10

OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR OPODIO IS A LIAR LIAR LIAR LIAR LIAR LIAR

[l0ngterm] 06/4/2018 23:06

Ham u are famous

[l0ngterm] 06/4/2018 22:00

You guys are so missing the point

[miavoce] 06/4/2018 21:55

The structure of the database and the data within it will be well understood by the CRO.

The datapoints to be reported in the headline report will have been pre-agreed.

The queries to produce these datapoints will have been preprepared and tested.

All that is needed to produce the headline results is to run the preprepared queries against the data.

Whilst I'm sure there will be some QA to be done, I don't see why the headline results can't be produced quickly so I'm expecting to see them at some point next week - possibly even as early as Monday if they are working the weekend.

[harbourside] 06/4/2018 21:40

Njb, from reading your comments and others on here I also believe the 16th or there about seems the most logical date for results. Do like the intrigue though of the company pulling a blinder and setting up SM for Monday’s talk, would catch a few on the hop. Alas that sort of stuff only happens in films, real life is much more mundane and predictable. GLA holders.

[ashehzi] 06/4/2018 21:35

I've managed complex Oracle databases for more than a decade. Complex queries can be run manually or via BI reports or using bespoke applications. All must be a day in day out job for CROs. Surely they can get summary reports quickly, if not complete analysis documents. In short, if not formal, at least informal results can be shared.

Having said that, I'm happy to wait for the results whenever they come via rns.

[l0ngterm] 06/4/2018 20:25

Not really mate

[hamhamham1] 06/4/2018 20:23

Time will tell

[l0ngterm] 06/4/2018 20:22

Nor disrespect meant ham

[l0ngterm] 06/4/2018 20:20

Ham you are out of your depth now

[hamhamham1] 06/4/2018 20:14

Che7. If there were a lot more buyers than sellers then the price would be a lot higher. Stop trying to fond excuses foe the market consensus.

[l0ngterm] 06/4/2018 20:07

I expect the shares to drop on Monday to roughly 166, maybe 160. Unless the buyer is still in, because the shares are being carried just now.

[fuji99] 06/4/2018 19:54

Che7win - Agree that derampers trying to push price down to buy as many shares as possible.

[ny boy] 06/4/2018 19:52

Just one last observation, a decent volume day 3M shares traded approx. kind of expected, new tax year etc. buys & sells almost evenly spread, nothing untoward about today’s price action, onwards we go to a new week, still happy to hold, see no reason to sell, one has come this far, finishing line coming up, you are invested if you believe in SM’s team etc Everything points to top line results.

[njb67] 06/4/2018 19:47

Harbourside

From my earlier posts on timings of results.

Once the database is locked, there is quite a lot of work to be done before the results are announced. The most time consuming of which will be that the CRO will need to produce a formal report of the interim results for IMM - sample attached.

hxxp://www.maps.org/research-archive/mdma/MP-2_CSR_FINAL_15Sep11.pdf

Our company target is sixteen weeks for a full study report from data lock. An interim report covering just the headline results can be generated much quicker but still takes time. A couple of weeks.

IMM will then need time to the review report before preparing and issuing a press release.

If SO were able to lock the database no later than today, have the foot to the floor, work all weekend etc., then it is possible that we could get results at the end of next week - Friday 13th anyone? I think w.c 16 April is much more likely.

GLA

[hottingup] 06/4/2018 19:24

From another website -

ImmuPharma Expects Top-Line Results of Lupuzor Phase 3 Trial by Mid-April
APRIL 4, 2018

Jose Marques Lopes, PhDBY JOSE MARQUES LOPES, PHD IN NEWS.
ImmuPharma Expects Top-Line Results of Lupuzor Phase 3 Trial by Mid-April

Top-line results of ImmuPharma£s Phase 3 clinical trial testing Lupuzor (rigerimod) as a systemic lupus erythematosus (SLE) treatment are expected by mid-April, according to the company.

ImmuPharma also announced that database lock of the trial is expected by April 6. This milestone prevents unauthorized or unintended alterations to the information obtained during the double-blind study (NCT02504645). This is especially relevant for double-blind trials, in which investigators do not know if they are using the treatment candidate or a placebo.

The 52-week study, which began in June 2016, evaluated the effectiveness and safety of Lupuzor plus standard therapy in SLE patients. The trial was conducted at 30 centers worldwide.

A total of 200 adults were randomly assigned to receive 200 micrograms of Lupuzor or placebo under the skin every four weeks for 48 weeks. All patients also received the standard therapy.

In January 2018, ImmuPharma announced the trial£s completion. Results showed a robust safety profile over one year of treatment with Lupuzor, also known as IPP-201101.

"With the continued robust safety record of [Lupuzor] achieved over this trial, we look forward with confidence to reporting top line results in the near future," Tim McCarthy, chairman of ImmuPharma, said in a press release.

The company also announced that, following requests from both patients and researchers, it was initiating an extension study with participants from the Phase 3 trial, who will receive Lupuzor plus standard therapy for an additional six months. Data analysis in this follow-up study will be independent from that of the Phase 3 trial, the company said.

Lupuzor is intended to regulate the immune system without affecting healthy cells, allowing them to remain active to fight infections. The investigational medication inhibits the activation of auto-reactive T-cells £ a type of white blood cell £ which attack the body£s own tissues. ImmuPharma says that Lupuzor£s ability to avoid targeting healthy cells makes it different from other immune-modulating therapies.

ImmuPharma announced the recent updates after they were informed of them by Simbec-Orion, the company conducting the research.

Lupuzor had been granted fast track designation by the U.S. Food and Drug Administration, which is intended to speed up development and approval of new treatments that meet unmet medical needs. The FDA had also approved a special protocol assessment for Lupuzor£s clinical trials, which means the agency will accept the studies£ results if they are positive.

hxxps://lupusnewstoday.com/2018/04/04/lupuzor-phase-3-trial-top-line-results-mid-april-immupharma-

[ny boy] 06/4/2018 19:24

Best every just chills until mid April, not long to go anyway.

As the result is hugely significant either way, if there was a leak as to the likely outcome, for sure the share price would start moving up or down by a large amount and on high volumes, small 5-15% moves are not a leak, just punters buying or selling MM’s playing around, leak news, if it did come out would be definitely much more noticeable.

Right catch on Monday good weekend all invested.

[h2owater] 06/4/2018 19:12

Rigerimod (Lupuzor ) to will commercialize Rigerimod,

Cephalon Taken over by Teva, $20 billion in revenues.


-------------------------------------
In addition to the US trial and in order to prepare for the commercial development in Japan, Cephalon has entered into a separate sub-licence agreement with Symbio Pharmaceuticals . Under the agreement, Cephalon retains all commercialisation rights to Rigerimod (Lupuzor ) in Japan, and Symbio is granted an exclusive right to conduct a Japanese-based Phase I clinical study which is mandatory for a future filing of Rigerimod (Lupuzor ) with the Japanese regulatory bodies.

Dimitri Dimitriou, Chief Executive Officer of ImmuPharma said: "We are extremely encouraged with the progress Cephalon is making with regards to the US trials, first steps into Japan and importantly their commitment to the Lupuzor programme."






----------------------------------------------------
Teva Completes Acquisition of Cephalon
-- Combined organization will provide customers with a broad spectrum of specialty branded products in addition to the world's largest generic drug portfolio--

JERUSALEM, Oct 14, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for the twelve months ended June 2011.

"This important transaction reinforces Teva's long term strategy of building out our branded and specialty pharmaceuticals business through diversification and expansion of our product portfolio and pipeline, while enhancing our position as the worldwide leader in generics," said Shlomo Yanai, President and CEO of Teva. "Our newly-expanded portfolio in CNS, Oncology, Respiratory and Women's Health along with our robust pipeline of more than 30 late-stage products truly cements our position as a leader in specialty pharma."